Tuesday, October 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Wedbush Analyst Reiterates Confidence in Kura Oncology with Outperform Rating and 37 Price Target

Elaine Mendonca by Elaine Mendonca
February 28, 2024
in Breaking News
0
Investings on laptop and finances
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Wedbush analyst Robert Driscoll has once again expressed his confidence in Kura Oncology (NASDAQ: KURA), giving it an “Outperform” rating and sticking with a $37 price target. This reiteration underscores Driscoll’s optimism about the company’s future performance and attractiveness to investors. The ongoing support from Wedbush highlights their belief in Kura Oncology’s ability to grow and maintain a strong position in the market.

KURA Stock Shows Strong Performance with 4.92% Increase on February 28, 2024

On February 28, 2024, KURA stock showed strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock.

The price of KURA shares increased by $1.02 since the market last closed, representing a 4.92% rise from the previous closing price of $21.76. This significant price increase is a bullish signal for investors, suggesting that there is strong buying interest in the stock.

Kura Oncology Inc. (KURA) Financial Data Analysis: Decrease in Net Income but Improvement in EPS – February 28, 2024

On February 28, 2024, investors were closely watching the stock performance of Kura Oncology Inc. (KURA) as the company’s financial data was released. According to CNN Money, KURA’s total revenue was currently unavailable, which may have raised some concerns among investors. However, the net income figures provided showed a decrease in both the yearly and quarterly comparisons.

In the past year, KURA reported a net income of -$135.84 million, which was a 4.12% decrease from the previous year. In the third quarter, the company’s net income was -$38.60 million, representing a 3.84% decrease from the previous quarter. These declining net income figures may have contributed to the uncertainty surrounding KURA’s stock performance on February 28.

Despite the decrease in net income, there was a slight improvement in earnings per share (EPS) for KURA. The company reported an EPS of -$2.03 for the past year, which was a 3.13% decrease from the previous year. However, in the third quarter, KURA’s EPS was -$0.50, showing a 6.16% increase from the previous quarter. This improvement in EPS may have provided some reassurance to investors amidst the declining net income figures.

Overall, KURA’s stock performance on February 28, 2024, may have been influenced by the mixed financial data released by the company. The lack of total revenue information, coupled with the decrease in net income, may have raised some concerns among investors. However, the improvement in EPS in the most recent quarter may have helped to mitigate some of these concerns. Investors will likely continue to monitor KURA’s financial performance closely in the coming months to assess the company’s future prospects.

Tags: KURA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Energy Company Markets and money

Global Partners LP Positioned for Strong Growth in 2024

Tech-banking-finance

Koppers Holdings Forecasts Strong Financial Performance for 2024

GD stock news

Analyst Maintains Neutral Rating on Revolve Group with Updated Price Target

Recommended

Remitly Global Stock

Remitly’s Market Paradox: Record Profits Amid Executive Share Sales

2 months ago
PayPal Stock

PayPal’s Strategic Revamp Sparks Renewed Investor Interest

2 months ago
MultiPlanration Stock

Claritev Shares Face Pressure Despite Strong Institutional Backing

4 weeks ago
Intellia Therapeutics Stock

Intellia Therapeutics Stock Surges Following Critical Clinical Trial Milestone

4 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Netflix’s Pivotal Earnings Report to Test New Profit Strategy

Tech Sector Roars Back as Meta Leads Market Rally

Rocket Lab Shares Surge on Growing Japanese Contract Pipeline

Strategic Moves Position Synopsys for Automotive Software Dominance

Kraft Heinz Shares Face Critical Test Amid Steep Decline

Is UPS’s High Dividend Yield a Value Trap?

Trending

Federal Home Loan Mortgage Stock
Banking & Insurance

Mortgage Giant Freddie Mac Faces Potential Privatization Shift

by Andreas Sommer
October 21, 2025
0

The prospect of privatization has resurfaced for Freddie Mac, with the Trump administration actively exploring options to...

Block (ex Square) Stock

BlackRock Takes Major Stake in Fintech Firm Block

October 21, 2025
C3.ai Stock

C3.ai Faces Critical Juncture Amid Legal and Financial Challenges

October 21, 2025
Netflix Stock

Netflix’s Pivotal Earnings Report to Test New Profit Strategy

October 21, 2025
Meta Stock

Tech Sector Roars Back as Meta Leads Market Rally

October 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Mortgage Giant Freddie Mac Faces Potential Privatization Shift
  • BlackRock Takes Major Stake in Fintech Firm Block
  • C3.ai Faces Critical Juncture Amid Legal and Financial Challenges

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com